Nonnucleoside Analogues

(Delavirdine, Efavirenz, Nevirapine)

Courtney V. Fletcher, Pharm.D.

Professor and Chairman
Dept. of Clinical Pharmacology
Univ. of Colorado Health Sciences Center
4200 East Ninth Ave., Box C-238
Denver, CO 80262

Tel: (303) 315-5229

Fax: (303) 315-4630

Email:  courtney.fletcher@uchsc.edu

Michael Para, M.D.

The Ohio State Univ. Medical Center
Dept. of Internal Medicine
Columbus, OH

Email:  para.1@osu.edu

Susan Swindells, MBBS

CLASS

Chemical Structure

               Discovered in 1990, nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a structurally diverse group of compounds with potent and selective in vitro activity against human immunodeficiency virus (HIV)-1 (68, 79, 4, 41, 42, 34, 35, 107, 78). A collection of chemically distinct agents, nonnucleoside reverse transcriptase inhibitors include dipyridodiazepinones such as nevirapine, bis(heteroaryl)piperazine compounds such as delavirdine, benzoxamines such as efavirenz, benzophenone analogues such as GW4751, GW4511, and GW3011 (18), diaryltriazine (DATA) compounds and dianilinopyrimidine (DAPY) compounds such as TMC125-R165335 (Das), and trifluoromethyl-containing quinazolin-2(1H) compounds such as DPC-082, DPC-083, DPC-961, and DPC-963. The chemical structures of the three licensed nonnucleoside reverse transcriptase inhibitors are shown in Figure 1.

               The three FDA approved NNRTIs are nevirapine, delavirdine and efavirenz, and several compounds are in clinical development. Benzophenone analogues such as GW4751, GW4511, and GW3011, a DAPY molecule known as TMC125-R165335, and DPC-083, a trifluoromethyl-containing quinazolin-2(1H) compound, have all demonstrated in vitro activity against strains of HIV resistant to the currently marketed NNRTIs (28, 18). However, more clinical data are needed to declare these compounds the next generation of NNRTIs. This review will focus on the commercially available NNRTIs, nevirapine, delavirdine, and efavirenz, as a significant amount of data from human studies are available and these compounds will continue to be developed, and offer utility to the practicing clinician treating HIV-infected individuals.

Structure-Activity Relationship

               Despite their diverse molecular compositions, nonnucleoside reverse transcriptase inhibitors share a common relationship between chemical structure and antiviral activity. Unlike nucleoside reverse transcriptase inhibitors, which are incorporated into viral DNA, all nonnucleoside reverse transcriptase inhibitors inhibit HIV-1 by binding directly to the reverse transcriptase molecule. Reverse transcriptase directs the polymerization of DNA from viral RNA, an essential step in viral replication. Nonnucleoside reverse transcriptase inhibitors appear to inhibit polymerization allosterically by altering the position of critical amino acids within the catalytic site of the reverse transcriptase enzyme. The description of the crystal structure of reverse transcriptase by Kohlstaedt and colleagues in 1992 helped to demonstrate the binding of nonnucleoside reverse transcriptase inhibitors to the enzyme complex (59). The structure of reverse transcriptase is analogous to that of a right hand, with the p66 subdomain folded into several separate regions, often referred to as “fingers,” “palm,” and “thumb.” Nonnucleoside reverse transcriptase inhibitors bind into a deep pocket that lies between the “palm” and the base of the “thumb.” This suggests a mechanism by which the inhibitors may act like sand in the gears of a machine, altering molecular movement essential for viral replication. The chemical reaction catalyzed by reverse transcriptase is significantly slowed in the presence of nonnucleoside reverse transcriptase inhibitors (9, 91, 33). This structure-activity relationship also explains the high degree of specificity of these agents for HIV-1 reverse transcriptase.

ANTIVIRAL ACTIVITY

Spectrum

               The antiviral activity of all nonnucleoside reverse transcriptase inhibitors is highly selective for HIV-1. The compounds do not exhibit activity against other viruses, including HIV-2 or other animal lentiviruses (60). Nonnucleoside reverse transcriptase inhibitors are highly potent antiretroviral drugs in vitro (68, 79, 4, 41, 42, 34, 35, 5, 6, 107, 78). Inhibition of reverse transcriptase at nanomolar concentrations has been reported, with minimal cytotoxicity in a variety of cell lines. Synergy has been observed in vitro between nonnucleoside reverse transcriptase inhibitors and nucleoside analogs (83, 16). Nonnucleoside reverse transcriptase inhibitors are also active against some nucleoside resistant strains; for example nevirapine is active against zidovudine-resistant HIV-1 in vitro (12). Inhibitory activities of nevirapine, delavirdine and efavirenz are shown in a variety of cell lines in Table 1. The nucleoside analogues zidovudine and didanosine are also shown for comparison.

Pharmacodynamic Effects

Nevirapine

               In vitro, nevirapine is active against HIV-1, including strains that are resistant to zidovudine, and is synergistic with zidovudine, didanosine, stavudine, lamivudine, and saquinavir (12). The in vitro 50% inhibitory concentration (IC₅₀) ranges from 0.01 to 0.1 µM. To achieve 95% and 100% inhibition in vitro, nevirapine concentrations of approximately 1 and 10 µM, respectively, are necessary (83). The relationship between in vitro inhibitory values and concentration in the plasma necessary to achieve sustained inhibition of HIV-1 replication is not known. For example, nevirapine was administered in daily doses of 12.5, 50 and 200 mg to 62 HIV-infected persons with CD4 counts < 400 cells/µL. Steady-state trough concentrations at 12.5, 50, and 200 mg/day were 0.9, 4, and 7 µM, respectively, indicating that at the lowest dose trough concentrations were essentially above the in vitro 50% inhibitory concentration at all times and were 70 times above at the highest dose. Yet, no patient achieved a sustained virologic response and all patients in the study had nevirapine-resistant HIV strains within 8 weeks of therapy initiation (20).

               Clinical information on relationships between the plasma concentration of nevirapine and anti-HIV effect are sparse and conflicting. Eighteen HIV-infected adults received 400 mg/d of nevirapine and were evaluated for virologic response, defined as at least a 50% reduction in immune complex-dissociated p24 antigen from baseline sustained for 8 weeks. Ten patients remained in the study for approximately 8 weeks and were available for response analysis: eight were classified as responders. The median trough nevirapine concentration was higher in responders than in the nonresponders (18 µM versus 12 µM, p=0.02) (48). Further work is necessary to establish a relationship between plasma concentration and anti-HIV effect of nevirapine. Additionally, for nevirapine, delavirdine, efavirenz, and all other antiretroviral drugs, the correlation between in vitro susceptibility values including the most relevant index (IC₅₀, IC₉₀), and target plasma concentration needs to be elucidated.

Delavirdine Mesylate

               Delavirdine belongs to a class of compounds known as bisheteroarylpiperazines that have shown in vitro activity against HIV-1 reverse transcriptase. Similar to other nonnucleoside reverse transcriptase inhibitors including nevirapine and efavirenz, delavirdine has no activity against the reverse transcriptase of HIV-2. The in vitro 50% inhibitory concentration of delavirdine for HIV-1 averages 0.26 µM (35). Delavirdine has a high degree of selectivity for HIV-1 reverse transcriptase in that concentrations 2,000-fold higher are required to inhibit cellular polymerases in vitro. As with nevirapine and efavirenz, the relationship between concentrations required to inhibit HIV-1 replication in vitro and that necessary to achieve sustained inhibition in vivo, is not known. The typical adult dose of 400 mg thrice daily produces average trough concentrations of approximately 16 µM, although there is considerable interpatient variability (37). While this trough is considerably greater than the average 50% inhibitory concentration, when adjusted for the high degree of binding to plasma proteins (average 98%), the free concentration of delavirdine would only be approximately 0.32 µM. Available data do support some clinical anti-HIV activity of delavirdine mesylate at the dose of 400 mg thrice daily. However, the effect appears quite weak, and perhaps not equivalent, when combined with zidovudine as compared to a nucleoside combination of zidovudine plus didanosine (29). One potential explanation for this weak antiretroviral effect may be the low ratio of free-drug plasma concentration to the in vitro inhibitory concentration.

Efavirenz

               Efavirenz belongs to the benzoxamine class of NNRTIs. The in vitro 90% inhibitory concentration of efavirenz for HIV-1 ranges from 1.7 to 25 nM. After adjustment for protein binding, these inhibitory concentrations range between 0.34 to 5 µM (14). Efavirenz has demonstrated synergistic activity against HIV-1 in cell culture when combined with NRTIs such as zidovudine, didanosine, and PIs, such as indinavir. Efavirenz exhibits a high degree of selectivity in that it does not inhibit HIV-2 or human cellular DNA polymerases alpha, beta, gamma and delta. As with other NNRTIs, the exact relationship between concentrations required to inhibit HIV-1 replication in vitro and those necessary to achieve sustained inhibition in vivo is unknown. The typical adult dose of efavirenz is 600 mg once daily. This regimen achieves typical values of 12.9 µmol/L for Cmax, and 5.6 µmol/L for Cmin. These data would suggest that in the majority of isolates, efavirenz concentrations in plasma will exceed the 90% in vitro inhibitory values by several fold; at the extreme of the susceptibility range; however, trough efavirenz concentrations may only approximate the protein binding adjusted 90% inhibitory concentration.

               Clinical data do support relationships between efavirenz concentrations and anti-HIV response. In dose ranging studies conducted during the clinical development of efavirenz, treatment failure was found to be three times as frequent when efavirenz trough concentrations were < 3.5 µM (1.1 mg/L) than when trough concentrations were above this value. The probability of treatment success was estimated to be approximately 90% when trough concentrations were approximately 10 µM (3.2 mg/L), and was estimated to approach 100% when trough concentrations were approximately 20 µM (6.3 mg/L). In an analysis of efavirenz plasma concentrations in 130 HIV-infected individuals, concentrations obtained between 8 to 20 hours post dose (14 + 2.7 hours) were found to predict both treatment failure and central nervous system (CNS) side effects (67). Virologic failure was observed in 50% of patients with efavirenz concentrations < 1 mg/L (≈ 3.2 µM), compared with failure rates of 22% and 18% in patients with concentrations between 1-4 mg/L or > 4 mg/L, respectively. CNS side effects were approximately three times more common in patients with efavirenz concentrations > 4 mg/L compared with patients who had concentrations between 1-4 mg/L.

MECHANISMS OF ACTION

               Treatment for HIV infection has thus far focused on suppression of viral replication by inhibition of essential viral enzymes. HIV-1 reverse transcriptase remains an attractive target for antiretroviral therapy as there is no related cellular homolog for reverse transcriptase, and the enzyme is essential for viral replication. Reverse transcriptase controls multiple activities and is required prior to provirus production early in the life cycle of the virus. Clinical benefit has been demonstrated using the seven licensed nucleoside/tide analogues: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, tenofovir and emtricitabine (106). All have exhibited the ability to suppress HIV-1 replication to varying degrees in vitro and in human studies.

               The mechanism of action of nonnucleoside reverse transcriptase inhibitors is distinct from that of the nucleoside analogues. Nucleoside or nucleotide reverse transcriptase inhibitors constrain HIV replication by incorporation into the elongating strand of viral DNA, causing chain termination. In contrast, nonnucleoside reverse transcriptase inhibitors are not incorporated into viral DNA but inhibit HIV-1 replication directly, in a unique fashion, by binding noncompetitively to HIV-1 reverse transcriptase (86, 105, 94, 38). The drugs bind to a hydrophobic pocket in the enzyme-DNA complex close to the active site catalytic residues (94). The mechanism of action of nonnucleoside reverse transcriptase inhibitors does not interfere with nucleotide binding. Unlike nucleoside analogs, nonnucleoside reverse transcriptase inhibitors do not inhibit human DNA polymerases. With their unique specificity for HIV-1, these agents are not active against other viruses, including HIV-2.

MECHANISM OF RESISTANCE

Organisms Commonly Resistant

               As antiretroviral drug use becomes more widespread, there is an ever-increasing number of HIV infected individuals who develop drug resistant virus. These viruses may be passed to others who acquire a drug resistant strain. The incidence of HIV drug resistance in new HIV infections is under intense scrutiny since it undermines therapeutic interventions and standardized recommendations for initial drug therapy. Resistance of HIV-1 to NNRTIs in recently infected patients, as evidenced by specific mutations in the RT gene (seen on genotypic assays) or resistance as measured in recombinant virus resistance assays (phenotypic assays), has been reported from a number of countries (82). In recently infected persons in the US, Little et al (62) reported an increase HIV’s resistance to NNRTIs from 1.7% in 1995-1998 to 7.3% in 1999-2000. The K103N substitution in the reverse transcriptase enzyme, most commonly associated with NNRTI resistance, was seen in 2% of the recently infected patients and significant levels of phenotypic drug resistance to the NNRTI class (>10 fold that of the reference strain) were found in 2-3% of new infections. These trends support recommendations for the use of resistance testing in patients with acute or early HIV infection (51).

               On the other hand, up to 30 % of the viral isolates from antiretroviral naïve HIV infected patients may have low levels of drug resistance (IC₅₀, 4-10 fold increased) or may show “atypical” substitutions of nucleotides within the reverse transcriptase gene. These substitutions are at the positions that are usually associated with NNRTI drug resistance mutations (e.g. 103) but other nucleic acid substitutions are present. Patients with these “atypical” substitutions or low-level resistance (<10 fold) show no worse virologic outcome with NNRTI use and they represent polymorphisms in the reverse transcriptase (RT) gene rather than true background drug resistance (24, 46).

Mechanisms of Resistance

               As with all other antiretroviral agents, the mechanism of development of resistance of HIV-1 to nonnucleoside reverse transcriptase inhibitors is by mutation of the reverse transcriptase gene in the viral genome. Suppression of wild type virus during NNRTI therapy permits the outgrowth of minority populations of drug-resistant variants. The nucleic acid substitutions in the reverse transcriptase gene, which confer reduced susceptibility to nonnucleoside reverse transcriptase inhibitors, are located in the nonnucleoside binding pocket of the enzyme where the inhibitors physically interact (34, 59, 105).

               Both steric inhibition of drug binding and increased rates of dissociation of the enzyme drug-complex have been described, depending on the particular amino acid substitution involved (65, 93). These mutations appear to reduce viral fitness to a limited extent and most NNRTI selected mutant viruses are both resistant and fit. In the presence of the drug, continued high-level replication of the drug resistant mutant allows accumulation of additional mutations that achieve even higher levels of drug resistance (30). Such multiply substituted viral strains are also more resistant to the newer experimental NNRTIs that have activity against viruses with single or double mutations.

               When nonnucleoside reverse transcriptase inhibitors are used as monotherapy for HIV-1 infection, drug resistance rapidly develops. In vitro resistance to nevirapine has been observed after only a few passages of infected cells in the presence of the drug (84).

               Similarly, clinical trials of monotherapy with nevirapine (48) and delavirdine (77) have shown resistance within a few weeks of drug initiation. Drug resistance mutations have even been found after a single dose of nevirapine given for perinatal prophylaxis (58).

               Initial in vitro and in vivo studies of NNRTIs suggested that there might be somewhat distinct RT mutations associated with viral resistance to each agent and gave hope that sequential use of NNRTIs would be possible. In the first clinical studies of NVP monotherapy, the most common RT mutation leading to drug resistance was a substitution of tyrosine with a cysteine at position 181 of the RT gene (Y181C). By week 12 of therapy 100% of the 24 subjects in this study had >100 fold increased IC50 and 19 (80%) of them had the Y181C. A substitution at V106A was also noted with continued NVP use (48). However, when thymidine analogs were used in combination with nevirapine, the majority of drug resistant isolates develop a K103N mutation, with subsequent accumulation of substitutions at Y188L and G190S (31).

               In vitro studies showed the major drug resistance mutation of delavirdine was a P236L substitution in the reverse transcriptase. Interestingly, this mutation sensitized the virus to NVP (36). Yet, the delavirdine monotherapy trial (ACTG 260) showed the P236L mutation to develop in less than 10% of patients with DLV resistance (32). Demeter’s group has shown the P236L mutation leads to reduced replication fitness relative to K103N which may explain the emergence of the K103N rather than the P236L mutant (39). In the ACTG 260 trial, the K103N was seen alone (48%) or in association with the Y181C mutation (30%) and while of 19% of patients had Y181C alone (32).

               In the phase II combination trials of efavirenz with zidovudine and lamivudine or efavirenz with indinavir, therapeutic failure was associated with the emergence of an RT mutation at K103N (90%). Subsequently, these subjects developed additional mutations including L100I, V108I, or P225H. The Y181C mutation that does not cause high level efavirenz resistance was not seen (7). Viruses carrying the L100I or K103N mutations have a 20- to 30-fold increase in their efavirenz IC₅₀. The combination of K103N with another substitution as L100I, V108I or P225H leads to more than a 100-fold increase in the IC₅₀. Those patients failing EFV without a K103N develop Y188L and/or G190S mutations. Table 2 shows the spectrum of mutations in the RT gene associated with drug resistance to nevirapine, delavirdine and efavirenz (27).

               Mutations in RT correlate with clinical and/or virologic failure of the NNRTI. There is a close correlation between the codon substitutions and reduced in vitro susceptibility. Reduced in vitro susceptibility has been observed to varying degrees with each codon mutation. Fold increase in susceptibility for some commonly selected mutations as compared to wild-type virus are shown in Table 3 (80).

               More recently, in vitro evidence suggests that a Y318F mutation in the 3’ end of RT caused NNRTI resistance. This led to a search for clinical isolates with this mutation. Review of data from a large phenotypic-genotypic database (Virco) showed decreased NNRTI susceptibility in 85% of clinical isolates with Y318F. There was also significant association of these isolates with past delavirdine and nevirapine use. Combinations of this mutation with other NNRTI associated resistance mutations further reduced viral susceptibility (45).

               Recombinant in vitro susceptibility assays express drug susceptibility as fold change of the IC50 of the patient isolate compared to a wide type reference virus. Recently, investigators have noted that some patient isolates appear in vitro more susceptible to select antiretroviral agents, i.e. less drug is needed to inhibit viral replication. These viruses are referred to as “hypersusceptible”. NNRTI naïve patients with prior nucleoside analogue reverse transcriptase inhibitor (NRTI) exposure, who have isolates with resistance mutations and phenotypic resistance to NRTIs, appear more likely to have hypersusceptibility to the NNRTI class of drugs (103). The clinical significance of this phenomenon, e.g. improved treatment response to NNRTIs, has recently been investigated by several groups (89). Haubrich et al (47) found that patients with longer duration of exposure to and reduced susceptibility to NRTIs were more likely to have EFV hypersusceptibility. In their patients treated with EFV, the mean fall in HIV RNA and mean CD4 rise was greater in those who had hypersusceptibility to EFV than those who did not.

Methods to Overcome and Prevent Resistance

               As with other antiretroviral agents, methods to prevent HIV drug resistance have utilized combinations of antiretrovirals. While dual combination of a NNRTI and a single nucleoside have not resulted in sustained virologic suppression (20), triple drug combinations with two NRTIs plus an NNRTI have proven quite effective with prolonged viral suppression to undetectable levels (73, 43, 96).

               In fact, EFV in combination with two NRTIs has emerged as the preferred initial treatment regimen for HIV infection (54). There had also been reports suggesting efavirenz was more clinically effective than nevirapine (25). Recently a large open label randomized trial compared two triple drug combinations: stavudine and lamivudine plus either nevirapine or efavirenz to the quadruple regimen of stavudine and lamivudine plus both nevirapine and efavirenz. There were over 1,200 subjects randomized and 84% completed 48 weeks of the trial. Analysis of viral loads showed 67.8% of efavirenz recipients, 63.6% of nevirapine twice daily, 65% nevirapine once daily, and 61.7% of the 2 NNRTI arm achieved virologic success (RNA<50). The extent of virologic success was not significantly different in any of the arms of the trial (101).

               Alternatives to the triple drug combinations (NNRTI+ 2 NRTI) using NNRTI have been studied. The four-drug, double NNRTI arm (nevirapine + efavirenz) of the 2NN trial showed no additional virologic benefit and also showed increased toxicity and therefore should not be considered clinically useful. Studies that have evaluated the efficacy of NNRTI plus protease inhibitor (PI) combinations have been completed but are limited. The double drug combination of EFV and the PI, indinavir, was tested in nucleoside naïve and nucleoside-experienced patients and showed that durable virus suppression was achieved in 53% to 66% of patients treated in the intent-to-treat analysis (96, 85). Ongoing studies within the AIDS Clinical Trials Group (ACTG) are examining the NNRTI + PI combination of efavirenz + lopinavir/ritonavir. Based on the drug-drug interaction, the usual daily dose of lopinavir/ritonavir, 400 mg/100 mg is increased to 533 mg/133 mg per day.

               In patients who have failed treatment with nevirapine, the detection of only a Y181C mutation in the RT gene may suggest susceptibility to EFV and has generated clinical interest in testing this possibility. Unfortunately, EFV in vitro susceptibility was only found in half of the NVP failures and resulted in HIV suppression in only 17% of subjects at three months (3). In a report by Shulman, patients with Y181C had an initial virologic response to efavirenz, but this was lost by 12 weeks (90). In another report by Casado, 47 NVP- experienced patients with HIV RNA >1000 were placed on an efavirenz- based salvage regimen. Only 19% achieved undetectable levels of viral RNA and these were patients with shorter periods of NFV therapy (17).

               Thus the hope that NNRTI might have distinct resistance patterns has not been substantiated and cross-resistance among this class is common. NNRTI cross-resistance from clinical specimens, as measured using a recombinant virus phenotypic assay (Virco), is shown in Table 3 below (50). While there is extensive NNRTI cross-resistance, the good news is there is little overlap with mutations that confer resistance to nucleoside analogues or HIV-1 protease inhibitors.

PHARMACOKINETICS

Nevirapine

               Nevirapine is well absorbed after oral administration. Absolute bioavailability appears > 90% and maximum concentrations are generally achieved by 4 hours after an oral dose. Absorption was not affected by concomitant administration with a high fat breakfast, antacids, or didanosine (12). Nevirapine is widely distributed in humans; it is highly lipophilic, essentially not ionized at physiologic pH, and is approximately 60% bound to plasma proteins. Nevirapine concentrations in the cerebrospinal fluid of 6 individuals were 45% + 5% of corresponding plasma values: this ratio is approximately equivalent to the unbound fraction in plasma (40). Nevirapine readily crosses the placenta. This may be attributed to its low degree of protein binding (60%), a lower molecular weight (266), a relatively favorable degree of lipophilicity (log octanol:water partition coefficient 1.81) and/or because it is reportedly not a substrate of P-glycoprotein (66). One 200 mg oral dose of nevirapine administered to an HIV-positive mother during labor and a single 2 mg/kg dose administered to the newborn at 48-72 hours after birth maintains serum concentrations above 100 µg/L (10 times the in vitro 50% inhibitory concentration against wild-type HIV) throughout the first week of life. This regimen has been shown to reduce vertical transmission of the virus by nearly 50% in mothers and infants receiving no other antiretroviral therapy (70, 44). For women receiving a single 200 mg dose of nevirapine, cord blood concentrations will exceed 100 µg/L provided the baby is delivered at least 1-2 hours after maternal administration (71). Nevirapine is present in breast milk. In 20 Ugandan women who received a single 200-mg dose of nevirapine during labor, the median nevirapine concentration in breast milk 1 week after delivery was 103 ng/ml (25-309 ng/ml) (76). Although nevirapine concentrations in breast milk were maintained above 100 µg/L in this study, the total amount of drug provided to a nursing infant was small, approximately 0.06 mg/kg on day 2 of life and 0.02 mg/kg on day 7.

               Nevirapine is extensively metabolized by the cytochrome P450 system, principally by isozymes from the cytochrome 3A family. In a mass balance study in healthy volunteers, > 90% of a radiolabeled dose was recovered, mostly from the urine (81%) as glucuronidated metabolites (12). Renal excretion contributes little to the elimination of the parent compound. Nevirapine is also an inducer of cytochrome P450 enzymes, including those associated with its own metabolism. This autoinduction is characterized by a decrease in the terminal elimination half-life from approximately 45 hours after a single dose to 25-30 hours after 14 days of multiple doses, a 1.5 to 2-fold increase in apparent oral clearance, and a fall in trough concentrations (19, 48). Available data do not indicate race-related differences in the oral clearance of nevirapine (12). Data do indicate that the oral clearance of nevirapine is slower in women than in men (108). Pharmacokinetic studies of nevirapine in children do indicate that oral clearance is higher in children than in adults. Children receiving multiple-doses of nevirapine at 120-240 mg/m2/day had an oral clearance of approximately 0.08 mL/kg/d, a value two-fold greater than that found for adults (64).

Delavirdine Mesylate

               Delavirdine mesylate is a weak base with very low solubility at pH > 3. While the drug is usually rapidly absorbed after oral administration, reaching maximum concentrations within 1.5 hours following a dose, absorption can be delayed and reduced by an increase in gastric pH (38, 87). For example, simultaneous administration with an antacid reduced the delavirdine area under the concentration curve (AUC) by 48% (38). Food and didanosine also appear to delay and reduce delavirdine absorption; although, under steady-state conditions these interactions do not appear to be clinically significant and patients can be allowed to take delavirdine with a meal, and with didanosine (74). In general, gastric hypoacidity or therapeutic agents that raise gastric pH should be expected to decrease delavirdine absorption and reduce plasma concentrations; delavirdine administration under these conditions should be avoided until proven otherwise.

               Delavirdine is highly (98%) protein bound, which restricts systemic distribution (DLV PI). The penetration of delavirdine into cerebrospinal fluid appears quite low and likely clinically insignificant; in 5 adults, cerebrospinal fluid concentrations were 0.4% of corresponding plasma concentrations (29, 2). Delavirdine is extensively metabolized, and renal clearance of unchanged drug is a negligible route of elimination. The cytochrome P450 system and isozymes of the 3A family are a significant pathway of metabolism for delavirdine. Delavirdine is not only a substrate for this enzyme system but is also an inhibitor. Thus, delavirdine (and/or its metabolites) can actually inhibit its own metabolism, and this appears responsible for the nonlinearities observed in delavirdine pharmacokinetics (22). These nonlinearities are characterized by a decrease in oral clearance, an increase in the terminal elimination half-life, and a greater than proportional increase in plasma concentrations with higher doses of delavirdine. Steady-state plasma concentrations, for example, at 600 mg daily, average 9.2 µM and 2.3 µM for maximum and minimum, respectively. A two-fold increase in dose to 1200 mg daily produced a four-fold increase in maximum concentrations to 36 µM and a seven-fold increase in minimum values to 16 µM (38). Furthermore, delavirdine pharmacokinetics are highly variable between patients. As one illustration of this variability, the range in delavirdine trough concentrations in patients receiving 1200 mg daily appears to be from < 5 µM to approximately 50 µM, a more than ten-fold difference. This high degree of variability in delavirdine pharmacokinetics is consistent with known interpatient differences in cytochrome P450 activity.

               Delavirdine pharmacokinetics has not been studied in individuals under 16 or over 65 years. The median delavirdine AUC was shown to be 31% higher in 12 females compared with 55 males receiving the standard dose of 400 mg thrice daily (2). At this time, dosing recommendations are the same for females and males. No significant racial difference in delavirdine trough concentrations has been reported.

Efavirenz

               Efavirenz is well absorbed after oral administration. Peak efavirenz concentrations of 1.6-9.1 µmol/L were attained by 5 hours following single oral doses of 100-1600 mg to uninfected volunteers. In HIV-infected patients, 600 mg daily doses produced an average Cmax of 12.9 µmol/L, Cmin of 5.6 µmol/L, and oral clearances of 0.18 L/hr/kg (96). Steady state plasma concentrations were reached in 6-10 days. The administration of efavirenz tablets and capsules with a high-fat meal (>54 g fat) should be avoided as it results in an increase in efavirenz AUC and Cmax. At standard adult doses, efavirenz exhibits linear pharmacokinetics. Efavirenz is highly protein bound (approximately 99%). CSF concentrations in 10 patients receiving 600 mg daily averaged 35.1 nM, significantly higher than the reported IC90 for wild-type HIV-1. The penetration of efavirenz into the CSF ranged from 0.26-0.99% of total plasma concentrations, generally consistent with unbound concentration in plasma (99). Efavirenz has a terminal half-life of 52-76 hours after a single dose and 40-55 hours after multiple doses, as a result of autoinduction. CYP3A4 and CYP2B6 are the major isoenzymes responsible for the metabolism of efavirenz. Less than 1% of unchanged drug is excreted in the urine (14), therefore no dosage adjustment is required for reduced renal function. A study of a single 400 mg dose of efavirenz in 10 patients with chronic liver disease demonstrated a 35% decrease in Cmax and an increased half-life compared to healthy volunteers; however, there was no significant change in AUC. Monitoring for toxicity in these patients is warranted. During Phase II trials of efavirenz, Black and Pacific Island races were noted to have reduced clearance of efavirenz compared to Caucasians, but this was not found in the analysis of Phase III trial data (11). Efavirenz has demonstrated inhibiting and inducing abilities for several isoenzymes in the cytochrome system, which will be discussed further in the drug interactions section. Pharmacologic parameters of nevirapine, delavirdine, and efavirenz are shown in Table 5.

DOSAGE  (TABULAR)

Adults and Children

Adult Dosing: The usual adult doses of nevirapine, delavirdine and efavirenz are shown in Table 6.

Pediatric Dosing: Nevirapine and efavirenz have both been clinically evaluated in children, and nevirapine is approved for use in children 2 months of age and older, and efavirenz is approved for use in children three years of age and older. For both drugs, children require a higher dose on a weight or body surface area basis than adults to maintain acceptable plasma concentrations. In a pharmacokinetic study of multiple-dose nevirapine, children 2 months to 13 years of age were administered 240 mg/m2/day of nevirapine following an induction-phase dose of 120 mg/m2/day. Oral clearance rates correlated with age and, consistent with enzymatic activity predictions, children 2 years of age and younger had the highest rates of nevirapine clearance, which was double the adult rate. The FDA approved doses of nevirapine for use in children are: for children 2 months up to 8 years of age, 4 mg/kg once daily for the first 14 days followed by 7 mg/kg twice daily thereafter. For children 8 years and older, the recommended dose is 4 mg/kg once daily followed by 4 mg/kg twice daily thereafter. It is recommended that the total nevirapine dose not exceed 400 mg (12). Safety and effectiveness of delavirdine have not been established in HIV-1 infected individuals younger than 16 years of age (2).

               Efavirenz has been shown to be a highly effective drug in children and adolescents and has a relatively low incidence of adverse effects, and a prolonged half-life allowing once daily dosing. The FDA approved efavirenz dose ranges between 10-20 mg/kg/day for children three years of age or older and weighing between 10 and 40 kg, which is about double the recommended adult dose, reflecting the higher clearance of efavirenz on a weight basis in children compared with adults (95). Efavirenz dosing for pediatric patients 3 years of age or older and weighing between 10 and 40 kg is listed below (14).

Efavirenz Pediatric Dose

               The recommended dosage of efavirenz for pediatric patients weighing greater than 40 kg is 600 mg, once daily.

Renal Failure

               Dose adjustment for renal insufficiency (mild to severe < 30 mL/min), does not appear necessary for nevirapine. However, subjects requiring dialysis exhibited a 44% reduction in nevirapine AUC over a one-week exposure period and an additional 200 mg dose following each dialysis is recommended (14, 57, 56, 100). Dose adjustment for renal insufficiency for delavirdine has not been well studied but does not appear to be necessary (2). The pharmacokinetics of efavirenz have not been studied in patients with renal insufficiency; however, less than 1% of efavirenz is excreted unchanged in the urine, so the impact of renal impairment on efavirenz elimination should be minimal and dose adjustment for renal insufficiency does not appear necessary (14).

Hepatic Failure

               In the majority of patients with mild or moderate hepatic impairment, no significant changes in the pharmacokinetics of nevirapine were seen in a single dose study but an increase in the AUC of nevirapine has been observed in one patient with Child-Pugh Class B and ascites. This suggests that patients with severe hepatic function and ascites may be at risk of accumulating nevirapine and the manufacturer recommends that nevirapine not be administered to patients with severe hepatic impairment (12). It is also recognized that the risk for hepatotoxicity from nevirapine is increased in persons with chronic hepatitis.

               The pharmacokinetics of delavirdine, and efavirenz have not been evaluated in patients with hepatic dysfunction. Nevertheless, these agents are metabolized primarily by the liver and should be used with caution in patients with impaired hepatic function.

Body Composition

               Neither weight nor age (range 18-68 years) appears to affect dosing requirements of nevirapine for adults (12, 75). However, none of the three NNRTIs have been extensively evaluated in patients beyond the age of 65 years.

Ascites/Edema

               The effect of ascites or edema on pharmacokinetic disposition has also not been evaluated for any of the NNRTI agents.

Diarrhea/Malabsorption

               Nevirapine has similar absorption whether taken with a fatty meal or administered with antacids or fasting (12).

               Delavirdine tablets may be administered with or without food. HIV-infected subjects with gastric hypoacidity significantly malabsorb delavirdine so patients with achlorhydria should take this drug with an acidic beverage (e.g., orange or cranberry juice).  Delavirdine administration with acidic beverages improves, but dose not normalize, absorption in these subjects (88).

               It is recommended that efavirenz be taken on an empty stomach, preferably at bedtime. The increased efavirenz concentrations observed following administration of this drug with food might lead to an increase in frequency of CNS side effects (14).

Malnutrition

               It is not known whether malnutrition alters the pharmacokinetics of nevirapine, delavirdine or efavirenz.

Pregnancy

               No dosage adjustment is recommended for NNRTI therapy during pregnancy. All three approved drugs are FDA Category C and delavirdine and efavirenz have demonstrated rodent teratogenicity. Delavirdine has been associated with some ventricular septal defects, and efavirenz caused malformations in 3 of 20 fetal cynomolgous monkeys. These malformations included anencephaly, anophthalmia and microphthalmia, therefore, efavirenz should not be administered during pregnancy.

               Nevirapine is the best studied and best tolerated antiretroviral agent used to prevent perinatal transmission and its use is recommended by the several consensus guidelines (54).

ADVERSE EFFECTS

Nevirapine

               The most common adverse effects associated with nevirapine therapy are rash and hepatitis. Severe, life threatening, and in some cases fatal hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis and hepatic failure, have been reported (12). Serious hepatic events occur most frequently during the first 12-16 weeks of therapy although may occur at any time during treatment. Patients with signs or symptoms of hepatitis should be evaluated promptly with liver function testing and be advised to discontinue nevirapine as soon as possible. Serious hepatotoxicity (including liver failure requiring transplantation in one instance) has even been reported in HIV-uninfected individuals receiving multiple doses of nevirapine in the setting of post-exposure prophylaxis (72).

               Co-infection with hepatitis B and/or C, a CD4+ T cell count of more than 350 cells/mm3 prior to the start of antiretroviral therapy and female gender all seem to be associated with increased risk of hepatic adverse events with nevirapine.

               Rash has been reported with nevirapine therapy in 15 – 30% of patients and may require discontinuation in about 7% (12, 75, 10). A 14-day lead-in period of 200 mg/day (4 mg/kg/day in pediatric patients) has been shown to reduce the frequency of rash and is generally recommended (21). If rash is observed during the lead-in period, dose escalation should not occur until the rash has resolved. The rash is most commonly maculopapular and mild to moderate. Although the precise mechanism is unclear, skin biopsies have demonstrated nonspecific inflammatory changes and some have shown perivascular infiltration consistent with a drug eruption. Immune complex deposition has not been observed. Rash typically occurs within six weeks of initiation of treatment and, in general, the rashes are self-limiting and rarely require treatment although antihistamines and topical steroid therapy can be used. However, severe, life-threatening skin reactions, including fatal cases, have been reported with nevirapine treatment and include Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction. Some of the risk factors for developing serious cutaneous reactions include failure to follow the initial dosing of 200 mg daily during the 14-day lead-in period and delay in stopping the nevirapine treatment after the onset of the initial symptoms. Women appear to be at higher risk than men of developing rash with nevirapine.

               In a clinical trial, concomitant prednisone use was associated with an increase in incidence and severity of rash during the first 6 weeks of nevirapine therapy and is therefore not recommended to try and prevent rash (104).

Delavirdine

               Rash is also a common adverse effect observed to date with delavirdine therapy with an overall incidence around 35% (2). The rash associated with delavirdine is also maculopapular occurring between 7 and 15 days after initiating treatment. The occurrence, but not severity, of the rash appears to correlate with CD4+ T-cell count and occurs more frequently in patients with <100 CD4 cells/mm3. Like nevirapine, the incidence of rash appears unrelated to dose or blood level of delavirdine. Pruritus occurs in one third of patients who develop rash though other symptoms have not been observed. Clinical trial experience has demonstrated that continuing treatment is possible in >85% of patients who develop rash (38). Dosing through the rash with medication for symptomatic relief, or dose interruption with resumption at a lower dose that is increased over two weeks, have both been successful. Severe skin reactions are rare with delavirdine. Other adverse effects are headache, fatigue, and gastrointestinal complaints, including occasional increase in transaminase levels (2).

Efavirenz

               The most common adverse effects with efavirenz therapy are central nervous system symptoms, rash and hepatitis. Nervous system symptoms have been reported by 53% of subjects receiving efavirenz in controlled trials compared to 25% receiving control regimens (14). These symptoms include (in order of frequency): dizziness, insomnia, impaired concentration, somnolence, abnormal dreams, and hallucinations. Generally mild to moderate and self-limiting (within 2 – 4 weeks), these symptoms led to discontinuation of therapy in only 2% of cases. Dosing at bedtime may improve the tolerability of these nervous system symptoms and patients should be alerted to the potential for additive central nervous system effects when efavirenz is used concomitantly with alcohol or psychoactive drugs, and to avoid potentially hazardous tasks such as driving or operating machinery.

               Serious psychiatric adverse experiences have also been reported including severe depression, suicidal ideation, non-fatal suicide attempts, aggressive behavior, paranoid reactions and manic reactions. Patients with a history of psychiatric disorders may be at greater risk of these serious psychiatric adverse experiences, and many providers avoid using the drug in patients at risk. As with the other drugs in this class, rash can occur in up to 26% of patients. Severe rash is rare; the median time to onset of rash in adults was 11 days and the median duration was 16 days (14). Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash.

               Unlike other antiretroviral drug classes, the NNRTIs are not commonly associated with metabolic complications after long-term therapy. The exception to this is the potential contribution of efavirenz to HIV-associated dyslipidemia although the mechanism underlying this is not known (98).

Overdose

               There are no known antidotes for overdosing with nevirapine, delavirdine or efavirenz. Cases of nevirapine overdose at doses ranging from 800 to 1800 mg per day for up to 15 days have been reported (12). Treatment of over dosage with NNRTIs includes general supportive measures and elimination of unabsorbed drug by emesis, gastric lavage or administration of activated charcoal, if indicated. Since delavirdine and efavirenz are extensively metabolized by the liver and highly protein bound, dialysis is unlikely to result in significant removal of the drugs.

MONITORING REQUIREMENTS

Therapeutic Drug Monitoring

               In general, antiretroviral agents meet most of the characteristics of agents that can be considered as candidates for a therapeutic drug monitoring (TDM) strategy. For NNRTIs, the rationale for TDM arises in particular from data showing considerable interpatient variability in concentrations among patients who take the same dose, and data indicating relationships between the concentration of drug in the body, the anti-HIV effect and in some cases, toxicity. The data describing relationships between anti-HIV agents and response have been reviewed in various publications (1, 8, 15, 49).

               There are limitations and unanswered questions in these data; however, the data do provide a framework for the potential implementation of TDM for NNRTIs and consensus guidelines of US and European clinical pharmacologists have been published (55). The recommended threshold trough concentration for patients with wild-type virus susceptibility to nevirapine is 3.4 mg/L. Support for this value arises in large part from the INCAS trial that demonstrated patients with nevirapine concentrations above 3.4 mg/L reached undetectable levels of HIV-1 RNA in plasma more rapidly than those who had lower trough concentrations. In this study, the median nevirapine plasma concentration was significantly correlated with success of therapy after 52 weeks (102).

               The recommended threshold trough concentration for efavirenz is 1.0 mg/L in patients with wild-type virus susceptibility. In a study of 130 patients with HIV on an efavirenz-based antiretroviral regimen, 50% of patients with an efavirenz trough of less than 1 mg/L experienced virologic failure versus 22% in patients with efavirenz concentrations between 1-4 mg/L. This same study showed that CNS toxicity was approximately three times more frequent in patients whose efavirenz levels exceed 4 mg/L (67). Guidelines for the collection of blood samples and other practical suggestions can be found in a position paper published by the Adult AIDS Clinical Trials Group Pharmacology Committee (1, 55).

Other Laboratory Monitoring

               Liver function tests should be monitored in patients on NNRTI therapy, especially during the first few weeks of therapy. The optimal frequency of monitoring during this time period has not been established but most experts recommend clinical and laboratory monitoring at baseline, prior to dose escalation and at two weeks post-dose escalation. After the initial treatment period, periodic laboratory monitoring should continue at a minimum of every 3 months. Monitoring of cholesterol and triglycerides should be considered in patients treated with efavirenz.

DRUG INTERACTIONS

               Nevirapine, delavirdine, and efavirenz have the potential to cause clinically significant drug interactions. Nevirapine is an inducer of hepatic cytochrome P450 3A; maximal induction seems to occur within two to four weeks of multiple dosing. Thus, nevirapine has the potential ability to decrease concentrations of other agents metabolized by these same isozymes. For example, nevirapine has been shown to decrease saquinavir maximum concentrations by 29% and the AUC by 27% and this combination should be avoided (12). The effect of nevirapine on the pharmacokinetics of indinavir has been evaluated in 24 HIV-infected persons. The indinavir AUC was 28% lower, peak concentration 11% lower, and trough concentration 38% lower when administered with nevirapine (12). These results appear consistent with the known ability of nevirapine to induce the hepatic cytochrome enzyme 3A. An increase in the dose of indinavir to 1000 mg every 8 hours, or the addition of ritonavir is recommended if indinavir and nevirapine are to be co administered however, the clinical safety, tolerance, and antiviral effect of this combination has not been evaluated. The effect of nevirapine on the pharmacokinetics of ritonavir has also been evaluated. This combination was studied in 24 HIV-infected persons, although only 14 had evaluable data. Results indicate that the ritonavir AUC was 11% less, peak concentrations were 10% lower, and trough concentrations 9% lower when given with nevirapine. These differences were not statistically significant, and no changes in the ritonavir dosing regimen are recommended (13). Neither indinavir nor ritonavir affected the pharmacokinetics of nevirapine. The AUC of nelfinavir may also be reduced necessitating an increased nelfinavir dose, but clear guidelines are lacking for these combinations.

               As an inducer of metabolism, nevirapine has a theoretical ability to decrease the plasma concentrations of oral contraceptive agents and increase the risk of contraceptive failure. Concomitant administration of nevirapine at steady state and ethinyl estradiol/norethindrone resulted in a 29% reduction in ethinyl estradiol AUC and an 18% reduction in norethindrone AUC in 10 HIV-infected women (69). Therefore, oral contraceptives should not be the primary method of birth control in women of childbearing potential who are treated with nevirapine. Several case reports have described methadone withdrawal of varying degrees in patients receiving nevirapine therapy. Pharmacokinetic studies support these findings, with 40-50% reductions in methadone AUC in patients initiated on a nevirapine-containing antiretroviral regimen. There is however, wide inter-individual variability, and not all patients require increases in methadone dosage (23, 97). Nevirapine can reduce zidovudine plasma concentrations by approximately 25% (26). This interaction is most likely a result of induction of glucuronyl transferase activity by nevirapine. Nevirapine has had no effect on the pharmacokinetics of either didanosine or zalcitabine (12).

               Nevirapine is extensively metabolized by the cytochrome P450 system and is a substrate for isozymes from the 3A family. Therefore, the metabolism of nevirapine has the potential to be increased by inducers, or decreased by inhibitors of these enzymes. Rifampin and rifabutin are well-known enzyme inducers and have been shown to reduce steady-state nevirapine trough concentrations by 37% and 16%, respectively (12). Co-administration of nevirapine with these compounds should be avoided. Ketoconazole is an enzyme inhibitor, and was shown in in vitro experiments to inhibit nevirapine metabolism. However, pharmacokinetic studies in 11 patients receiving nevirapine and ketoconazole found no apparent inhibition of nevirapine metabolism. These contradictory findings seem to warrant additional clinical investigation, especially because cimetidine and macrolide antibiotics have both been shown to inhibit nevirapine metabolism and increase trough concentrations by 21% and 12%, respectively (12).

               Like nevirapine, the metabolism of delavirdine is mediated by hepatic cytochrome enzymes including those of the 3A family. Thus, there exists the potential for the clearance of delavirdine to be affected by inducers or inhibitors of these isozymes. Concomitant administration of delavirdine with rifabutin decreased delavirdine concentrations by five-fold, while administration with rifampin decreased concentrations by 27-fold (38). Neither rifabutin nor rifampin should be co administered with delavirdine. Fluconazole and clarithromycin are inhibitors of hepatic drug metabolism. Clinical investigations have found that fluconazole did not affect delavirdine metabolism, and that there was no overall significant interaction between delavirdine and clarithromycin. However, clarithromycin does have some ability to inhibit delavirdine metabolism and there may be certain patients particularly susceptible to this interaction. While there is no apparent contraindication to concomitant administration of these two agents, careful clinical monitoring of delavirdine tolerance is recommended.

               Delavirdine, in contrast to nevirapine, is a potent inhibitor of hepatic metabolism. In healthy volunteers, delavirdine increased the AUC of indinavir by approximately 70 to 90% (2). On the basis of these data, the dose of indinavir would need to be reduced from the approved 800 mg every 8 hours if delavirdine and indinavir are given as combination therapy. An indinavir dose of 400 or 600 mg every 8 hours has been suggested, but clinical safety and efficacy data in HIV-infected patients are lacking. Delavirdine also inhibits the metabolism of saquinavir, increasing the steady-state concentration an average of six-fold (2). There appears to be considerable interpatient variability in the magnitude of this interaction, however, as individual trough saquinavir concentrations were increased from two- to 15-fold. Delavirdine did not demonstrate inhibition of ritonavir metabolism, nor did ritonavir affect the metabolism of delavirdine in a study in healthy volunteers. There are no available data on the combination of delavirdine and nelfinavir. Perhaps the most serious potential interactions with delavirdine exists in concomitant use with certain non-sedating antihistamines, such as terfenadine and astemizole, and other cytochrome P450 3A substrates like cisapride. Combinations of these agents and other inhibitors of cytochrome P450 3A have lead to significant arrhythmias that can be fatal (52, 81). The mechanism of this interaction is inhibition of metabolism of the parent drug, leading to accumulation of the parent drug, which can be cardiotoxic. Delavirdine is contraindicated for concomitant use with these agents.

               Efavirenz is principally metabolized by CYP 2B6 and 3A4 to hydroxylated metabolites with subsequent glucoronidation. In vitro, efavirenz is an inhibitor of CYP3A4, CYP2C9, and CYP2C19. However, its effect on CYP3A4 is mixed, as it has also been shown to induce this enzyme. Efavirenz also induces its own metabolism.

               When indinavir 800 mg thrice daily is co administered with efavirenz, the indinavir AUC is decreased by approximately 31% and Cmax decreased by 16%. It is therefore suggested that patients receive 1000 mg of indinavir thrice daily when used concomitantly with efavirenz, or have ritonavir added to their regimen (96, 48). Similarly, when co administered with efavirenz, lopinavir/ritonavir concentrations are reduced. Increasing the lopinavir/ritonavir dose to 533/133 mg twice daily when administered with efavirenz provides lopinavir/ritonavir concentrations similar to those achieved in the absence of efavirenz (53). Saquinavir AUC and Cmax were reduced by 62% and 50% respectively when dosed with efavirenz in a study of 12 healthy volunteers. Therefore use of saquinavir as a single protease inhibitor with efavirenz is not recommended, but coadministration of saquinavir with ritonavir could be considered (14).

               Rifamycins are commonly used in the treatment of mycobacterial infections associated with HIV disease. Rifabutin is often selected because it is a less potent inducer of CYP3A than the other rifamycins, thereby lessening the chances of reduced concentrations of antiretrovirals. However, rifabutin Cmax and AUC are reduced by 32% and 38% respectively when given with efavirenz. An increase in rifabutin dose to 450-600 mg daily may be warranted if patients are on an antiretroviral regimen that contains efavirenz and no protease inhibitor. Rifampin has been shown to decrease the Cmax and AUC of efavirenz by 20 and 26% respectively. It may be advisable to increase the efavirenz dose to 800 mg when concomitant treatment with rifampin is necessary (63).

               Methadone AUC is reduced by approximately 50% when administered with efavirenz. But, like nevirapine, reduced methadone concentrations do not always correlate with clinical effect. Physicians should monitor patients receiving methadone-maintenance who are initiating an efavirenz-based antiretroviral regimen for symptoms of withdrawal.

               Oral contraceptive concentrations are increased by efavirenz, but the clinical significance of this interaction is unknown.

CLINICAL INDICATIONS

               All three licensed NNRTIs are indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. These indications are based on clinical trials of at least one years’ duration demonstrating prolonged suppression of HIV-RNA (2, 12, 14). Unlicensed uses of these drugs include prevention of perinatal transmission, prevention of occupational exposure and prevention of non-occupational exposure (54). Nevirapine is not recommended for post-exposure prophylaxis because of reported cases of hepatotoxicity (72) and efavirenz may be problematic because of the central nervous system side effects and also potential teratogenicity in female health care workers of child bearing potential (14). Efavirenz and delavirdine should also be avoided during pregnancy because of teratogenic potential.

CONCLUSIONS

               NNRTIs have an established and important role in the treatment of HIV-1 infection. High antiviral potency, high specificity and minimal metabolic complications have all contributed to the popularity of NNRTI-based regimens. Many experts now consider the combination of Combivir (zidovudine and lamivudine) with efavirenz to be the “gold standard” of anti-HIV therapy. The major vulnerability of this class is the potential for rapid emergence of resistance with almost universal cross-resistance between NNRTIs. Promising second generation compounds are in development, several of which are the result of molecular modeling. These new agents are anticipated to expand the limitations of useful this class of antiretrovirals.

TABLES AND FIGURES

Table 1.  Inhibitory Activities of the Nonnucleoside Reverse Transcriptase Inhibitors Nevirapine, Delavirdine and Efavirenz in A Variety of Cell Lines.  The Nucleoside Analogues Zidovudine and Didanosine are also Shown for Comparison.

Table 2.  Mutations in the Reverse Transcriptase (RT) Gene Associated with Drug Resistance To NNRTI. 

Table 3. Fold Increase of IC₅₀ For Some Commonly Selected Mutations as Compared to Wild-Type Virus.

Table 4. NNRTI Cross-Resistance – Virco Database N=5000 (50). 

Table 5. Pharmacologic Parameters of Nevirapine, Delavirdine, and Efavirenz 
Table 6. The Usual Adult Doses of Nevirapine, Delavirdine, and Efavirenz. 

REFERENCES

1. Acosta EP, Gerber JG; Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002;18:825-834.[PubMed]

2. Agouron Pharmaceuticals, Inc. Rescriptor (delavirdine mesylate tablets) package insert. June 2001.[PubMed]

3. Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo MG, Trotta MP, Di Giambenedetto S, Narciso P, Ammassari A, Girardi E, De Luca A, Perno CF. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002;18:835-838. [PubMed]

4. Baba M, De Clercq E, Iida S, Tanaka H, Nitta I, Ubasawa M, Takashima H, Sekiya K, Umezu K, Nakashima H, Shigeta S, Walker RT, Miyasaka T. Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives. Antimicrob Agents Chemother 1990;34:2358-2363. [PubMed]

5. Baba M, De Clercq E, Tanaka H, Tanaka H, Ubasawa M, Takashima H, Sekiya K, Nitta I, Umezu K, Walker RT, Mori S. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Molec Pharmac 1991;39:805-810. [PubMed]

6. Baba M, De Clercq E, Tanaka H, Ubasawa M, Takashima H, Sekiya K, Nitta I, Umezu K, Nakashima H, Mori S. Potent and selective inhibition of human immunodeficiency virus type 1 by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc Natl Acad Sci 1991;88:2356-2360. [PubMed]

7. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, Becker MF, Lasut AL, George HJ, Spalding DR, Hollis G, Abremski K. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44:2475-2484.[PubMed]

8. Back D, Gatti G, Fletcher CV, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber A, Merry C, Perno CF. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002;16:S5-S37.[PubMed]

9. Bacolla A, Shih CK, Rose JM, Piras G, Warren TC, Grygon CA, Ingraham RH, Cousins RC, Greenwood DJ, Richman D. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2: effect on kinetic constants and inhibition by non-nucleoside analogs. J Biol Chem 1993;268:16571-16577. [PubMed]

10. Barner A, Myers M. Nevirapine and rashes. Lancet 1998;351:1133. [PubMed]

11. Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 2002; 40:507-519.[PubMed]

12. Boehringer Ingelheim Pharmaceuticals, Inc. Viramune (nevirapine) package insert. December 2002. [PubMed]

13. Boehringer Ingelheim Pharmaceuticals, Inc., Letter to Investigators, 1997. [PubMed]

14. Bristol-Myers Squibb Company. Sustiva (efavirenz) package insert. April 2002. [PubMed]

15. Burger DM, Aarnoutse RE, Hugen PWH. Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis 2002;15:17-22.[PubMed]

16. Campbell TB, Young RK, Eron JJ, D'Aquila RT, Tarpley WG, Kuritzkes DR. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atervidine (U-87201E) in combination with zidovudine or didanosine. J Infect Dis 1993;168:318-326.[PubMed]

17. Casado JL, Moreno A, Hertogs K, Dronda F, Moreno S. Extent and importance of cross-resistance to efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002;18:771-775. [PubMed]

18. Chan JH, Freeman GA, Tidwell JH, Romines KR, Schaller LT, Cowan JR, Gonzales SS, Lowell GS, Andrews CW 3rd, Reynolds DJ, St Clair M, Hazen RJ, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Koszalka GW, Boone LR. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem 2004;47:1175-1182. [PubMed]

19. Cheeseman SH, Hattox SE, McLaughlin MM, Koup RA, Andrews C, Bova CA, Pav JW, Roy T, Sullivan JL, Keirns JJ. Pharmacokinetics of nevirapine: Initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993;37:178-182. [PubMed]

20. Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M, Richman DD. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquired Immune Deficiency Syndrome 1995;8:141-151. [PubMed]

21. Cheeseman SH, Murphy RL, Saag MD, Havlir D, and ACTG 164/168 Study Team. Safety of high dose nevirapine (NVP) after 200 mg/d lead-in. In: Program and abstracts of the International Conference on AIDS; June 6-11, 1993; Berlin. Abstract PO-B26-2109. [PubMed]

22. Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther 1997;61:531-543. [PubMed]

23. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001;33:1595-1597. [PubMed]

24. Clevenbergh P, Cua E, Dam E, Durant J, Schmit JC, Boulme R, Cottalorda J, Beyou A, Schapiro JM, Clavel F, Dellamonica P. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naive HIV-infected patients. HIV Clin Trials 2002;3:36-44. [PubMed]

25. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, Piersantelli N, Orani A, Petrosillo N, Leoncini F, Scerbo A, Tundo P, Abrescia N, Moroni M; Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study Group. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study. J Infect Dis 2002;185:1062-1069. [PubMed]

26. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS, and the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Annals of Intern Med 1996;124:1019-1030. [PubMed]

27. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD; International AIDS Society-USA. Drug Resistance Mutations in HIV-1. Top HIV Med 2002;10:21-25. [PubMed]

28. Das K, Clark AD, Arnold E, Boyer PL, Hughes SH, Ludovici DW, De Corte BL, Kavash RW, Kukla MJ, de Bethune MP, Pauwels R, Andries K, Lewi P, de Jonge M, Daeyaert F, Koymans L, Vinkers M, Heeres J, Janssen PA. Could multiple modes of binding of a potent NNRTI TMC 125-R165335 explain its potency against common drug-resistant mutants? In vitro characterization of novel benzophenone non-nucleoside reverse transcriptase inhibitors. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, MA. [PubMed]

29. Davey RT, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, Eastman PS, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Boyle J, Coleman S, Cox SR, Wathen L, Daenzer CL, Lane HC. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type-1 infected patients. Antimicrob Agents and Chemother 1996;40:1657-1664.[PubMed]

30. Deeks SG. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syn 2001;26:S25-S33.[PubMed]

31. Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001;65:445-448. [PubMed]

32. Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC. Delavirdine susceptibilities and associated RT mutations in HIV-1 isolates from patients in a Phase I/II trail of delavirdine monotherapy (ACTG 260). Antimicrob Agent Chemother 2000;44:794-797. [PubMed]

33. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PA, Hughes SH, Arnold E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nature Struct Biol 1995;2:407-415. [PubMed]

34. Dueweke TJ, Kezdy FJ, Waszak GA, Deibel JR, Tarpley WG. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem 1992;267:27-30. [PubMed]

35. Dueweke TJ, Poppe SM, Romero DL, Swaney SM, So AG, Downey KM, Althaus IW, Reusser F, Busso M, Resnick L, Mayers DL, Lane J, Aristoff PA, Thomas RC, Tarpley WG. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993;5:1127-1131. [PubMed]

36. Dueweke TJ, Pushkarskaya T, Poppe S, Swaney SM, Zhao JQ, Chen IS, Stevenson M, Tarpley WG. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci 1993;90:4713-4717.[PubMed]

37. Freimuth WW, Chuang-Stein CJ, Greenwald CA, Cox SR, Edge-Padbury BA, Carbery PA, Wathen LK and Delavirdine Team, Pharmacia & Upjohn, Inc. Delavirdine (DLV) + didanosine (ddI) combination therapy has sustained surrogate marker response in advanced HIV-1 population. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections; January 28-February 1, 1996; Washington DC. Abstract LB8. [PubMed]

38. Freimuth WW. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. In: Mills J., ed., et al. Antiviral Chemotherapy 4. New York: Plenum Press, 1996:279-289. [PubMed]

39. Gerondelis P, Archer RH, Palaniappan C, Reichman RC, Fay PJ, Bambara RA, Demeter LM. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities. J Virol 1999;73:5803-5813. [PubMed]

40. Glynn SL, Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci 1998;87:306-310. [PubMed]

41. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM, Anderson PS, Hupe DJ, Emini EA, Stern AM. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA 1991;88:6863-6867.[PubMed]

42. Goldman ME, O'Brien JA, Ruffing TL, Nunberg JH, Schleif WA, Quintero JC, Siegl PKS, Hoffman JM, Smith AM, Emini EA. L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro. Antimicrob Agents Chemother 1992;36:1019-1023. [PubMed]

43. Green S, Para MF, Daly PW, Freimuth WW, Getchel LD, Greenwald CA, Wathen LK. 1998. Interim analysis of plasma viral burden reductions and CD4 increases in HIV-1 infected patients with delavirdine + Retrovir (ZDV) + Epivir (3TC). In: Program and abstracts of the Twelfth World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12219. [PubMed]

44. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802. [PubMed]

45. Harrigan PR, Salim M, Stammers DK, Wynhoven B, Brumme ZL, McKenna P, Larder B, Kemp SD. A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J Virol 2002;76:6836-6840. [PubMed]

46. Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, Brumme ZL, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.  Antivir Ther 2003;8:395-402. [PubMed]

47. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA; California Collaborative Treatment Group. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002;16:33-40.[PubMed]

48. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, Lamson M, Richman DD. High-dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-45. [PubMed]

49. Heeswijk RGP. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther Drug Monitoring 2002;24:323-331. [PubMed]

50. Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, Miller V, Larder BA. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 2000;14:1203-1210. [PubMed]

51. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D’Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel. Clinical Infectious Diseases 2003;37:113-128. [PubMed]

52. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-1518. [PubMed]

53. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Fooit C, Rynkiewicz K, Richards B, King M, Rode R, Kempf DJ, Granneman GR, Sue E. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003;47:350-359. [PubMed]

54. http://www.aidsinfo.nih.gov/  [PubMed]

55. http://www.hivpharmacology.com. Optimizing TDM in HIV clinical care. [PubMed]

56. Izzedine H, Launay-Vacher V, Aymard G, Legrand M, Deray G. Pharmacokinetic of nevirapine in haemodialysis. Nephrol Dial Transplant 2001;16:192-193. [PubMed]

57. Izzedine H, Launay-Vacher V, Deray G. Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis. Nephrol Dial Transplant 2001;16:643. [PubMed]

58. Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, Mofenson LM, Mirochnick M, Mmiro F, Eshleman SH. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000;14:F111-F115. [PubMed]

59. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 Å or resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992;256:1783-1790.[PubMed]

60. Koup RA, Merluzzi VJ, Hargrave KD, Adams J, Grozinger K, Eckner RJ, Sullivan JL. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone (BI-RG-587). J Infect Dis 1991;163:966-970. [PubMed]

61. Larder BA, Kemp SD, Purifoy DJ. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci 1989;86:4803-4807. [PubMed]

62. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. Antiretroviral-drug resistance among patients recently infected with HIV. NEJM 2002;347:385-394. [PubMed]

63. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, Leon-Jimenez E, Sarasanacenta M, Lopez-Pua Y, Pachon J. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002;41:681-690. [PubMed]

64. Luzuriaga K, Bryson Y, McSherry G, Robinson J, Stechenberg B, Scott G, Lamson M, Cort S, Sullivan JL. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996;174:713-721. [PubMed]

65. Maga G, Amacker M, Ruel N, Hubscher U, Spadari S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J Mol Biol 1997;274:738-747. [PubMed]

66. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, Buclin T; Swiss Mother + Child HIV Cohort Study. Transplacental passage of protease inhibitors at delivery. AIDS 2002;16:889-893. [PubMed]

67. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-75. [PubMed]

68. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J, Rosenthal AS, Faanea R, Eckner RJ, Koup RA, Sullivan JL. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;250:1411-1413. [PubMed]

69. Mildvan D, Yarrish R, Marshak A, Hutman HW, McDonough M, Lamson M, Robinson P. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 2002;29:471-477.[PubMed]

70. Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: Pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet 2000;39:281-293. [PubMed]

71. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL. Pharmacokinetics of nevirapine in human immunodeficiency virus tyupe 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998;178:368-374. [PubMed]

72. MMWR: Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures—worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001;49:1153-1156.[PubMed]

73. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JM. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-937. [PubMed]

74. Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M, Freimuth WW. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997;41:169-174.[PubMed]

75. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996;5:1183-1199.[PubMed]

76. Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999;13:479-486. [PubMed]

77. Para MF, Fischl M, Meehan P, Morse G, Wood K, Shafer K, Freimuth W, Demeter L, Holden-Wiltse J, and Nevin T. ACTG 260: a randomized, phase I-II dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. Antimicrob Agents and Chemother 1999;43:1373-1378.[PubMed]

78. Pauwels R, Andries K, Debyser Z, VanDaele P, Schols D, Stoffels P, DeVreese K, Woestenborghs R, Vandamme AM, Janssen CGM, Anne J, Cauwenbergh G, Desmyter J, Heykants, J, Janssen MAC, DeClercq E, Janssen PAJ. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci 1993;90:1711-1715.[PubMed]

79. Pauwels R, Andries K, Desmyter J, Schols D, Kula MJ, Breslin HJ, Raeymaeckers A, van Gelder J, Woestenborghs R, Heykants J, Schellekens K, Janssen MAC, DeClerq E, Janssen PA. Potent and selective inhibition of HIV-1 replication by a novel series of TIBO derivatives. Nature 1990;343:470-474. [PubMed]

80. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-928.[PubMed]

81. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Torsades de pointes after terfenadine-itraconazole interaction. BMJ 1993;306:186. [PubMed]

82. Porter K, Pillay D, Cane P, Dean G, Churchill D, Fisher M, Baily G, Drake S. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001;322:1087-1088. [PubMed]

83. Richman D, Rosenthal AS, Skoog M, Eckner RJ, Chou TC, Sabo JP, Merluzzi VJ. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991;35:305-308. [PubMed]

84. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J. Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991;88:11241-11245. [PubMed]

85. Riddler S, Kahn J, Martin G, Drusano G, Godofsky E, Havlir D, Ploughman LM, Manion D, Ruiz NM. Durable HIV suppression and tolerability with efavirenz + indinavir: results at 132 weeks (Study 003-Cohort IV). In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; Jan 30- Feb 2, 2000; San Francisco, CA, Abstract 513. [PubMed]

86. Romero DL, Busso M, Tan CK, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L, Tarpley WG. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block HIV-1 replication. Proc Natl Acad Sci USA 1991;88:8806-8810.[PubMed]

87. Shelton MJ, Akbari B, Hewitt RG, Adams JM, Morse GD. Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients. JAIDS 2000;24:79-82.[PubMed]

88. Shelton MJ, Hewitt RG, Adams JM, Cox SR, Chambers JH, Morse GD. Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J Clin Pharmacol 2003;43:171-179.[PubMed]

89. Shulman NS, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein DA, Israelski DM, Hellmann N, Petropoulos C, Whitcomb J. Phenotypic hypersusceptibility of non-nucleoside reverse transcriptase inhibitors in treatment experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 2001;15:1125-1132.[PubMed]

90. Shulman NS, Zolopa AR, Passaro DJ, Murlidharan U, Israelski DM, Brosgart CL, Miller MD, Van Doren S, Shafer RW, Katzenstein DA. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J Acquir Immune Defic Syndr 2000;23:221-226.[PubMed]

91. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA, Steitz TA. Structure of the biding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type. Proc Natl Acad Sci 1994;26:3911-3915.[PubMed]

92. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001;40:893-905.[PubMed]

93. Spence RA, Anderson KS, Johnson KA. HIV-1 reverse transcriptase resistance to non-nucleoside inhibitors. Biochemistry 1996;35:1054-1063. [PubMed]

94. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995;267:988-993. [PubMed]

95. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, Flynn PM. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. NEJM 1999;341:1874-1881. [PubMed]

96. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. NEJM 1999;341:1865-1873.[PubMed]

97. Stocker H, Kruse G, Kreckel P, Herzmann C, Arasteh K, Eskoetter H, Claus J, Jesen H, Cordes C, Hintsche B, Schlote F, Schneider L, Kurowski M. Nevirapine Significantly Reduces Methadone Levels in HIV-infected Patients. In: Program and abstracts of the Second IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract #867. [PubMed]

98. Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials 2003;4:29-36. [PubMed]

99. Tashima KT, Caliendo AM, Ahmad M, Gormley JM, Fiske WD, Brennan JM, Flanigan TP. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999;180:862-864. [PubMed]

100. Taylor S, Little J, Halifax K, Drake S, Back D. Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 2000;45:716-717.[PubMed]

101. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM; 2NN Study team.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63.[PubMed]
102. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D, Beijnen JH, Hoetelmans RM. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001;15:1089-1095. [PubMed]

103. Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 2002;16:F41-F47. [PubMed]

104. Wit FW, Wood R, Horban A, Beniowski M, Schmidt RE, Gray G, Lazzarin A, Lafeuillade A, Paes D, Carlier H, van Weert L, de Vries C, van Leeuwen R, Lange JM. Prednisolone does not prevent hypersensitivity with or without nevirapine. AIDS 2001;15:2423-2429. [PubMed]

105. Wu JC, Warren TC, Adams J, Proudfoot J, Skiles J, Raghavan P, Perry C, Potocki I, Farina PR, Grob PM. A novel, dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a non-substrate binding site. Biochemistry 1991;30:2022-2026. [PubMed]

106. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA, for the International AIDS Society-USA. Antiretroviral Treatment for Adult HIV Infection in 2002. JAMA 2002;288:222-235.[PubMed]

107. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, Pettibone DJ, O’Brien JA, Ball RG, Balani SK, Lin JH, Chen I-W, Schleif WA, Sardana VV, Long WJ, Byrnes VW, Emini EA. L-743726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995;39:2602-2605. [PubMed]

108. Zhou XJ, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA, Johnson VA, Myers M, Sommadossi JP. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999;43:121-128. [PubMed]

CLASS

               In 1887 it was recognized that extracts from cultures of Pseudomonas fluorescens inhibited the growth of bacteria (32). Four monoxycarbolic acids, pseudomonic acids A-D,

\